- Saxenda is the fourth drug for weight loss OK'd by the agency since 2012. ... "It is not an impressive weight loss for an injectable and expensive ...who would like to be get pricked every time for treatment where other options like OREXIGEN CONTRAVE is easy
"We are delighted with the CHMP opinion and look forward to the completion of the European Commission's review in early 2015," said Michael Narachi, CEO of Orexigen. "With both the US approval and this positive endorsement by the CHMP, we will advance our plans for partnership and commercialization of Contrave and Mysimba across the globe."
The main safety and tolerability concerns identified with Mysimba were related to central nervous system and gastrointestinal adverse events, and uncertainties with regard to cardiovascular outcomes in the longer term. Interim results from an ongoing cardiovascular outcome trial were reassuring in terms of risk of serious cardiovascular disease related to treatment with Mysimba. A second study is planned in order to continue monitoring longer-term cardiovascular safety with the medicine.
No difference was observed between groups in the incidence of depression, suicidal ideation, or hypoglycemia. CONCLUSIONS NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.
Xenical is the brand name for the prescription drug orlistat. ... Approved in 1999, Swiss pharmaceutical giant Roche's Xenical quickly amassed impressive sales, reaching a peak of $600 million in sales in .... May 23, 2014
Contrave, the anti-obesity drug from Orexigen (NASDAQ:OREX) saw weekly sales come in at just above 5,400 this past week. The drug has been on the market for 8 weeks now, and after a slow start due to technical issues, the last few weeks have been nothing short of impressive. In fact, the early launch of Contrave is presenting a trajectory that Arena (NASDAQ:ARNA) and Vivus (NASDAQ:VVUS) investors had hoped to see but fell short of. Prior to the Contrave launch, Arena's Belviq had set the bar.
What is it about Contrave that has the early numbers looking so impressive? In my opinion the price point is playing a major role. At this stage the trajectories of the competitors have not really degraded, but if you are invested in any drug in this sector, monitoring the overall sector is critical. It appears that the 900 sales reps dedicated to Contrave have actually helped to broaden the market. Certainly it is early, but there is no denying how impressive the last few weeks have been.
This report studies the global weight loss diets (food, beverages, & supplements), fitness and surgical equipment, and services, with forecast to 2017
The weight management market is divided into three segments, diets, services, and fitness and surgical equipment. The weight loss diets market includes food, beverages, and supplements. Weight loss food is the largest segment of the weight loss diets market, while beverages is the fastest-growing segment. The weight loss food market is further segmented as meal replacements, low-calorie ready meals, sugar free confectionaries, low-calorie desserts, and organic food.
The global weight loss/obesity management market was worth $265 billion in the year 2012 and is expected to reach $361 billion by 2017. The market will grow at a healthy pace in the next five years due to increasing number of lifestyle diseases such as diabetes and cardiac problems, increasing personal disposable income, government initiatives to increase awareness about health and fitness, and technological advancements.
US FDA approval was short raid under estimating Orex contrive scripts would be same like ARNA, Market but proved wrong with IMS data for just 2 weeks. But for EU its many BIG PHARMA open door for bidding war.
Russian Central Bank agreed to increase its Gold reserve through CHINA..Russian central bank preparing measures to pump money into banks in 2015
Analysis of the Light Study, a cardiovascular outcomes safety trial with more than 8,900 patients evaluating the effects of Mysimba on heart attack, stroke and cardiovascular death.
CHMP recommendation is happy with clinical data.
Final confirmation came from Vladimir himself. Yesterday the President of Russia gave his yearly press conference. When journalist Vyacheslav Terekhov (Interfax) asked about the crisis Russia currently is in, Putin made a clear statement:
19 Dec 2014 by Koos Jansen
Russia Is Not Selling Gold, Bought 18t In November
The final confirmation came from Vladimir himself. Yesterday the President of Russia gave his yearly press conference. When journalist Vyacheslav Terekhov (Interfax) asked about the crisis Russia currently is in, Putin made a clear statement: